User profiles for Lena Kaiser
 | Lena KaiserDepartment of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany Verified email at med.uni-muenchen.de Cited by 969 |
[HTML][HTML] Prediction of TERTp-mutation status in IDH-wildtype high-grade gliomas using pre-treatment dynamic [18F]FET PET radiomics
Purpose To evaluate radiomic features extracted from standard static images (20–40 min pi),
early summation images (5–15 min pi), and dynamic [ 18 F]FET PET images for the …
early summation images (5–15 min pi), and dynamic [ 18 F]FET PET images for the …
Binding characteristics of [18F]PI-2620 distinguish the clinically predicted tau isoform in different tauopathies by PET
The novel tau-PET tracer [ 18 F]PI-2620 detects the 3/4-repeat-(R)-tauopathy Alzheimer’s
disease (AD) and the 4R-tauopathies corticobasal syndrome (CBS) and progressive …
disease (AD) and the 4R-tauopathies corticobasal syndrome (CBS) and progressive …
[HTML][HTML] Feasibility of short imaging protocols for [18F]PI-2620 tau-PET in progressive supranuclear palsy
Purpose Dynamic 60-min positron emission tomography (PET) imaging with the novel tau
radiotracer [ 18 F]PI-2620 facilitated accurate discrimination between patients with progressive …
radiotracer [ 18 F]PI-2620 facilitated accurate discrimination between patients with progressive …
[HTML][HTML] Combination of pre-treatment dynamic [18F]FET PET radiomics and conventional clinical parameters for the survival stratification in patients with IDH …
Purpose The aim of this study was to build and evaluate a prediction model which incorporates
clinical parameters and radiomic features extracted from static as well as dynamic [ 18 F]…
clinical parameters and radiomic features extracted from static as well as dynamic [ 18 F]…
Toward single-time-point image-based dosimetry of 177Lu-PSMA-617 therapy
…, F Völter, LM Unterrainer, L Kaiser… - Journal of Nuclear …, 2023 - Soc Nuclear Med
Radiopharmaceutical therapies (RPTs) with 177 Lu-prostate-specific membrane antigen (PSMA)
ligands have demonstrated promising results for the treatment of metastatic castration-…
ligands have demonstrated promising results for the treatment of metastatic castration-…
[HTML][HTML] TSPO PET signal using [18F]GE180 is associated with survival in recurrent gliomas
S Quach, A Holzgreve, L Kaiser, M Unterrainer… - European Journal of …, 2023 - Springer
Purpose Glioma patients, especially recurrent glioma, suffer from a poor prognosis. While
advances to classify glioma on a molecular level improved prognostication at initial diagnosis, …
advances to classify glioma on a molecular level improved prognostication at initial diagnosis, …
Prognostic Value of TSPO PET Before Radiotherapy in Newly Diagnosed IDH–Wild-Type Glioblastoma
…, S Quach, K von Rohr, L Kaiser… - Journal of Nuclear …, 2023 - Soc Nuclear Med
The 18-kDa translocator protein (TSPO) is gaining recognition as a relevant target in
glioblastoma imaging. However, data on the potential prognostic value of TSPO PET imaging in …
glioblastoma imaging. However, data on the potential prognostic value of TSPO PET imaging in …
[HTML][HTML] Differential spatial distribution of TSPO or amino acid PET signal and MRI contrast enhancement in gliomas
L Kaiser, A Holzgreve, S Quach, M Ingrisch… - Cancers, 2021 - mdpi.com
Simple Summary Radiotracers targeting the translocator protein (TSPO) have recently
gained substantial interest, since TSPO is overexpressed in malignant gliomas, where it …
gained substantial interest, since TSPO is overexpressed in malignant gliomas, where it …
[HTML][HTML] Feasibility of radiomic feature harmonization for pooling of [18F] FET or [18F] GE-180 PET images of gliomas
…, JC Tonn, P Bartenstein, S Ziegler, L Kaiser - … für Medizinische Physik, 2023 - Elsevier
Introduction Large datasets are required to ensure reliable non-invasive glioma assessment
with radiomics-based machine learning methods. This can often only be achieved by …
with radiomics-based machine learning methods. This can often only be achieved by …
[HTML][HTML] 3D Monte Carlo bone marrow dosimetry for Lu-177-PSMA therapy with guidance of non-invasive 3D localization of active bone marrow via Tc-99m-anti …
Background The bone marrow (BM) is a main risk organ during Lu-177-PSMA ligand
therapy of metastasized castration-resistant prostate cancer (mCRPC) patients. So far, BM …
therapy of metastasized castration-resistant prostate cancer (mCRPC) patients. So far, BM …
